Therefore, we performed a retrospective multicenter study to explore the factors affecting the efficacy of crizotinib according to baseline next-generation sequencing data in patients with ALK rearrangement-positive advanced NSCLC. Here, ALK is linked to non-small cell lung carcinoma.